LONDON (Alliance News) - Plethora Solutions Holdings PLC said Tuesday that peak prescription sales of its topical spray for the treatment of premature ejaculation Fortacin could reach over USD1 billion a year.
The company expects to present this data to shareholders and potential investors at its US investor road-show in New York and Boston during the week.
Other data Plethora will present will include the potential pricing or Fortacin, showing it expects a fairly wide variance in pricing in the EU and US, with prices in the US expects to be lower than in the US.
The price per does is expected to be between USD6 to USD10 in the EU, and around USD17 per does in the US.
It also plans to clarify and confirm the time-lines expected for the new drug application filing and potential approval of the product in the US. It expects to complete filing of the new drug application including the new can size in the fourth quarter of 2015 or first quarter of 2016. Following filing, it expects a 10 month prescription drug user fee act review, with commercial launch in the US expected for 2017.
Shares in Plethora are trading down 5.5% at 6.50 pence Tuesday morning.
By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews
Copyright 2014 Alliance News Limited. All Rights Reserved.
